Mostrar el registro sencillo del ítem
dc.contributor.author | Ruiz Ortiz, Martín | |
dc.contributor.author | Muñiz, Javier | |
dc.contributor.author | Raña Míguez, Paula | |
dc.contributor.author | Roldán, Inmaculada | |
dc.contributor.author | Marín, Francisco | |
dc.contributor.author | Esteve Pastor, María Asunción | |
dc.contributor.author | Cequier, Ángel | |
dc.contributor.author | Martínez Sellés Oliveria Soares, Manuel | |
dc.contributor.author | Bertomeu, Vicente | |
dc.contributor.author | Anguita, Manuel | |
dc.contributor.author | Et al. | |
dc.date.accessioned | 2018-12-27T07:49:11Z | |
dc.date.available | 2018-12-27T07:49:11Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | Ruiz Ortiz, M., Muniz, J., Raña Míguez, P., Roldán, I., Marín, F., Esteve Pastor, M. A., ... & Anguita, M. (2018). Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry. EP Europace, 20(10), 1577-1583. https://doi.org/10.1093/europace/eux316 | spa |
dc.identifier.issn | 1099-5129 | |
dc.identifier.issn | 1532-2092 | |
dc.identifier.uri | http://hdl.handle.net/11268/7713 | |
dc.description.abstract | Aims To describe the prevalence and associated factors of inappropriate doses of direct oral anticoagulants (DOAC) in a national registry of patients of real clinical practice. Methods and results Five hundred and thirty outpatients with atrial fibrillation treated with DOAC were included in a prospective, national, multicentre study. The appropriateness of the doses of DOAC was defined according to the recommendations of the European Heart Rhythm Association. Mean age was 73 ± 9 years, with a 46% of women. Two hundred and sixty-seven patients were prescribed dabigatran, 190 rivaroxaban, and 73 apixaban. A total of 172 patients (32%) did not receive the appropriate dose: 93 patients received a lower dose (18%) and 79 patients a higher dose (15%). In the comparisons among the subgroups of inappropriately low, appropriate, and inappropriately high dose, we observed significant trends to older age (69 ± 8 years vs. 73 ± 10 years vs. 77 ± 6 years), more frequent female sex (37% vs. 46% vs. 59%), antiplatelet drugs (5% vs. 8% vs. 25%), rivaroxaban (14% vs. 38% vs. 53%), and apixaban use (5% vs. 15% vs. 19%), higher CHAD2DS2-VASc (3.00 ± 1.38 vs. 3.58 ± 1.67 vs. 4.59 ± 1.44) and HAS-BLED scores (1.83 ± 0.87 vs. 1.92 ± 1.07 vs. 2.47 ± 1.13), lower body mass index (30 ± 6 kg/m2 vs. 29 ± 4 kg/m2 vs. 28 ± 4 kg/m2) and glomerular filtration rate (74 ± 27 mL/min vs. 70 ± 22 mL/min vs. 63 ± 16 mL/min), and lower frequency of dabigatran use (81% vs. 47% vs. 28%) (all comparisons P ≤ 0.01). Conclusion In this real-life study, 32% of patients received an inappropriate dose of DOAC. Several clinical factors can identify patients at risk of this situation. | spa |
dc.description.sponsorship | Sin financiación | spa |
dc.language.iso | eng | spa |
dc.title | Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry | spa |
dc.type | article | spa |
dc.description.impact | 5.047 JCR (2018) Q1, 30/136 Cardiac & Cardiovascular Systems | spa |
dc.description.impact | 2.612 SJR (2018) Q1, 27/365 Cardiology and Cardiovascular Medicine, 7/108 Physiology (medical) | spa |
dc.description.impact | No data IDR 2018 | spa |
dc.identifier.doi | 10.1093/europace/eux316 | |
dc.rights.accessRights | closedAccess | spa |
dc.subject.uem | Farmacoterapia | spa |
dc.subject.uem | Fibrilación auricular | spa |
dc.subject.uem | Anticoagulantes | spa |
dc.subject.unesco | Enfermedad cardiovascular | spa |
dc.subject.unesco | Tratamiento médico | spa |
dc.subject.unesco | Medicamento | spa |
dc.description.filiation | UEM | spa |
dc.peerreviewed | Si | spa |
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |